A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
作者： Sun Jin Sym , Junshik Hong , Jinny Park , Eun Kyung Cho , Jae Hoon Lee
DOI: 10.1007/S00280-012-2027-3
关键词: Stomach cancer 、 Fluorouracil 、 Oncology 、 Gastroenterology 、 Refractory 、 Phases of clinical research 、 Internal medicine 、 Chemotherapy 、 Randomized controlled trial 、 Medicine 、 Confidence interval 、 Irinotecan
摘要: … In this trial, 40 metastatic or locally advanced gastro-oesophageal junction or gastric … a reasonable second-line chemotherapeutic backbone for patients with advanced gastric cancer. …
springer.com
sci-hub.se 参考文章(28)
A Wakui, T Taguchi, Y Sakata, M Yoshino, Y Shimada, K Futatsuki, I Nakao, N Ogawa, M Kambe, [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 21, pp. 1033- 1038 ,(1994)
Anna Dorothea Wagner, Nicholas LX Syn, Markus Moehler, Wilfried Grothe, Wei Peng Yong, Bee-Choo Tai, Jingshan Ho, Susanne Unverzagt, Chemotherapy for advanced gastric cancer Cochrane Database of Systematic Reviews. ,vol. 8, pp. 0- 0 ,(2017) , 10.1002/14651858.CD004064.PUB4
Andre M. Murad, Flavia F. Santiago, Andy Petroianu, Paulo R. S. Rocha, Marco A. G. Rodrigues, Marcelo Rausch, Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer. ,vol. 72, pp. 37- 41 ,(1993) , 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
S Pyrhönen, T Kuitunen, P Nyandoto, M Kouri, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. ,vol. 71, pp. 587- 591 ,(1995) , 10.1038/BJC.1995.114
Hai-Rim Shin, Kyu-Won Jung, Young-Joo Won, Jae-Gahb Park, , 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Research and Treatment. ,vol. 36, pp. 103- 114 ,(2004) , 10.4143/CRT.2004.36.2.103
V Catalano, F Graziano, D Santini, S D'Emidio, A M Baldelli, D Rossi, B Vincenzi, P Giordani, P Alessandroni, E Testa, G Tonini, G Catalano, Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? British Journal of Cancer. ,vol. 99, pp. 1402- 1407 ,(2008) , 10.1038/SJ.BJC.6604732
S T Kim, W K Kang, J H Kang, K W Park, J Lee, S-H Lee, J O Park, K Kim, W S Kim, C W Jung, Y S Park, Y-H Im, K Park, Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer British Journal of Cancer. ,vol. 92, pp. 1850- 1854 ,(2005) , 10.1038/SJ.BJC.6602575
Sun Jin Sym, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Tae Won Kim, Sung Sook Lee, Jung Shin Lee, Yoon-Koo Kang, Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. American Journal of Clinical Oncology. ,vol. 31, pp. 151- 156 ,(2008) , 10.1097/COC.0B013E31815878A2
Se Hoon Park, Eun Young Choi, Soo-Mee Bang, Euk Kyung Cho, Jae Hoon Lee, Dong Bok Shin, Woon Ki Lee, Min Chung, Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anti-Cancer Drugs. ,vol. 16, pp. 621- 625 ,(2005) , 10.1097/00001813-200507000-00005
Hiroya Takiuchi, Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials Gastric Cancer. ,vol. 14, pp. 206- 211 ,(2011) , 10.1007/S10120-011-0072-Y